- About
-
Services
-
Offerings
- Offerings
- ADME and Bioanalytical Sciences
- Analytical Chemistry
- Assay Development
- Biochemical Assays
- Biophysical Assays
- Cell Based Assays
- Computational Chemistry
- Fragment and Compound Screening
- Integrated Drug Discovery Services
- Medicinal Chemistry
- Protein Expression and Purification Services
- Structural Biology
- Synthetic Chemistry
- Virtual screening
-
Research Phases
- Research Phases
- Hit Identification
- Hit to Lead
- Lead Optimisation
- Therapeutic Areas
- Target Classes
-
Approaches & Techniques
- Approaches & Techniques
- CDH (Target Gene Fragmentation)
- Cryogenic Electron Microscopy (Cryo-EM)
- Differential Scanning Fluorimetry (DSF) and nanoDSF Services
- Direct-to-Biology (D2B)
- eProtein Discovery
- Flow Cytometry
- Fragment Based Drug Discovery (FBDD)
- FragmentBuilder
- Grating-Coupled Interferometry
- High Throughput Screening
- Isothermal Titration Calorimetry (ITC)
- LeadBuilder
- PoLiPa (Membrane Protein Solubilisation)
- Spectral Shift and MST Services
- Structure Based Drug Design (SBDD)
- Surface Plasmon Resonance (SPR)
- X-ray Crystallography
-
Offerings
- Library
- News & Events
- Careers
Join our webinar series discussing the latest developments in drug discovery. Register now.
Enquire
Awards & Accreditations
Recognition for our drug discovery services
Domainex is an award-winning integrated drug discovery services provider. In recent years we have been recognised by a range of industry bodies, celebrating our success as a team and as a business.
Financial Times ‘Europe’s Long-Term Growth Champions’
Domainex was included in the very first edition of the Financial Times ‘Europe’s Long-Term Growth Champions’ special report compiled in partnership with Statista.
This study aimed to identify and highlight European enterprises with long-term sustained organic growth. The 300 companies included in the list were selected from across all sectors and over 30 countries and all demonstrated substantial revenue growth between 2013 and 2023.
Cyber Essentials Plus
Domainex is committed to cyber security and is now Cyber Essentials Plus certified, confirming that we have taken measures to protect against cyber attacks.
King's Award for Enterprise: International Trade 2023
Domainex has received a King’s Award for Enterprise: International Trade 2023. This prestigious award recognises the company’s outstanding growth in international trade over three years (2019-2021) which amounted to a more than one hundred per cent increase in international revenues during the period.
Find out more in the following press releases:
Domainex secures a prestigious King’s Award for Enterprise
Best Drug Discovery Services Provider 2023
Domainex has been awarded the Best Drug Discovery Services Provider 2023 at the Global Health & Pharma Global Excellence Awards.
Cambridge Independent SME Awards 2023
Domainex was awarded Gold for High Growth Business of the Year and Silver for Business of the Year (>50 employees).
Business Weekly Awards
Domainex was honoured to receive the Life Sciences Scale-up Award 2023.
Best Drug Development, Discovery and Contract Research Organisation, 2022 - United Kingdom
Domainex has been awarded the Best Drug Development, Discovery and Contract Research Organisation, 2022 - United Kingdom at the Global Health and Pharma Global Excellence Awards.
SME National Business Awards 2022
Following success in the Cambridge regional awards, Domainex went on to win the Silver award for High Growth in the National Awards.
Cambridge Independent SME Awards 2022
Domainex was awarded a Gold award for High Growth Business of the Year and a Silver award for Business of the Year (more than 50 employees).
Leading Providers of Integrated Drug Delivery Services 2022
Domainex has been awarded the Leading Providers of Integrated Drug Delivery Services 2022 in the Global Health and Pharma International Life Sciences Awards.
Most Innovative Drug Discovery CRO 2022
Domainex has been awarded the Most Innovative Drug Discovery CRO 2022 in the Healthcare and Pharmaceutical Awards, gaining recognition for the third year in a row.
Best Drug Discovery CRO 2021
Domainex has been awarded the Best Drug Discovery CRO 2021 in the Healthcare and Pharmaceutical Awards 2021. After our success in 2020, Global Health & Pharma’s team of judges have recognised our services in this sector for the second year running.
2021 Freezer Challenge - Individual Laboratory Winner
Our Bioscience lab won a 2021 Freezer Challenge award, saving 48 kWh/day! The challenge is designed to encourage labs to optimise the sustainability of cold storage management and help change practices for the benefit of our environment.
Best CRO
We were named the Best CRO at the postponed OBN Awards 2020, awarded in June 2021. Following a very challenging period during the pandemic, the judges recognised our customer focus and the award would not have been possible without the hard work of our fantastic team. This is what allows Domainex to offer high quality services and remain a leader in the field of drug discovery.
Domainex wins Best CRO at OBN Awards
Drug Discovery CRO of the Year – Europe
At the Healthcare & Pharmaceutical Awards 2020, hosted by Global Health & Pharma (GHP), Domainex was awarded Drug Discovery CRO of the Year – Europe, recognising Domainex’s contribution to the industry and reflecting our expertise in drug discovery, dedication to customer service and commitment to promoting excellence.
Domainex recognised as leading drug discovery CRO
FT 1000
Domainex was ranked within the top 1000 fastest growing companies in Europe by the Financial Times in 2018. We were the only drug discovery CRO to have made this list.
Domainex ranked as the fastest growing drug discovery CRO in Europe
Start your next project with Domainex
Contact one of our experts today